The REACH-B Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B scoring system was developed to predict the risk of Hepatocellular carcinoma in noncirrhotic chronic Hepatitis B patients.
Dr Chen and colleagues evaluated the discriminatory performance of REACH-B scoring system in classifying treatment eligibility of chronic Hepatitis B patients according to the 2012 Asian Pacific Association for the Study of the Liver treatment guideline.
The researchers enrolled a total of 904 noncirrhotic chronic Hepatitis B were enrolled.
Patients' age, gender, liver biochemistry, HBeAg status and HBV DNA levels were recorded.
The minimum REACH-B risk score for patients to be eligible for treatment was 7 for HBeAg-positive, and 6 for HBeAg-negative patients.
The researchers noted that increasing REACH-B score was not significantly associated with eligibility for treatment in HBeAg-positive patients, as shown by logistic regression analysis after adjusting for gender.
|In HBeAg-negative patients, REACH-B score predicted the treatment eligibility|
|Alimentary Pharmacology & Therapeutics|
The team noted that in HBeAg-negative patients, REACH-B score significantly predicted the treatment eligibility.
Discriminatory ability of REACH-B score to classify eligibility was poor for HBeAg-positive patients 40 years, but good/excellent for HBeAg-positive patients 40 years, HBeAg-negative patients 45 years and HBeAg-negative patients 45 years
Dr Chan concludes "The discriminatory performance of the REACH-B scoring system in classifying treatment eligibility of hepatocellular carcinoma based on the 2012 APASL guideline was good/excellent, except for 40 years old HBeAg-positive patients."